When latest genetic analysis and therapeutic strategies are incorporated into MDS treatment the outcomes and quality of life in patients with MDS improves.

Recent research trials have incorporated the opinion coming from MDS patients themselves about their own quality of life to improve the assessment of several treatment options.

These changes to refine and strengthen diagnostic and risk-assessment models, along with the rapid evolution of disease management strategies that use standard of care and novel therapeutic agents, will likely further enhance clinical outcomes in patients with MDS and improve their quality of life.